The Drug Response Panel is a comprehensive next-generation sequencing (NGS) panel that can be used to determine a patient’s response to various drugs based on their genotype, which can assist in determining optimal dosing and reducing adverse events.
The Drug Response Panel covers hundreds of the most commonly prescribed drugs across of a large cross section of therapeutic areas. Genetic factors account for 20% to 95% of variability in response to individual drugs (Kalow et al, 1998) and 10% to 20% of adverse drug reactions may be related to genetic factors (Ingelman-Sundberg, 2004). Therefore, pharmacogenomic testing can reduce adverse drug reactions, help optimize dosing, and assist in selecting the most effective medication.
This test includes and reports only variant/drug relationships for which there is strong evidence of drug response being affected by a patient’s genotype. Therefore, this test only reports variant/drug relationships that have Clinical Pharmacogenetics Implementation Consortium (CPIC) evidence level of an A or B, a PharmGKB evidence level of 1 or 2, or are referenced in the FDA drug label.
The Drug Response Panel covers pharmacogenomics of drugs related to the following therapeutic areas (please see the Drug Response Gene List Sheet for a full list of assayed drugs):
Methodology and Analytical Sensitivity
Next-generation sequencing technology is used to test clinically relevant portions of each gene, including coding exons, adjacent flanking bases, and selected introns/noncoding variants. Pathogenic and likely pathogenic variants are confirmed by orthogonal methods. Copy number variants, including intragenic deletions and duplications are detected to a resolution of a single exon. Analytical sensitivity and specificity of the assay is >99%.
Indications for Testing
- Assessment of risk of altered metabolism of drugs based on genotype
Included Genes (85)
- Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200.
- Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–289.